ArticleCurrent neurovascular research2010
Diabetes mellitus: channeling care through cellular discovery.
Article in Current neurovascular research, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 32 citations in OpenAlex.
- The impact of aging and oxidative stress in metabolic and nervous system disorders: programmed cell death and molecular signal transduction crosstalk.Frontiers in immunology · 2023Review
- Innovative therapeutic strategies for cardiovascular disease.EXCLI journal · 2023Review
- New Insights for nicotinamide: Metabolic disease, autophagy, and mTOR.Frontiers in bioscience (Landmark edition) · 2020Review
- Nicotinamide: Oversight of Metabolic Dysfunction Through SIRT1, mTOR, and Clock Genes.Current neurovascular research · 2020Review
- Novel nervous and multi-system regenerative therapeutic strategies for diabetes mellitus with mTOR.Neural regeneration research · 2016Review
- Wnt1 Participates in Inflammation Induced by Lipopolysaccharide Through Upregulating Scavenger Receptor A and NF-kB.Inflammation · 2015Article
- Novel applications of trophic factors, Wnt and WISP for neuronal repair and regeneration in metabolic disease.Neural regeneration research · 2015Review
- mTOR: Driving apoptosis and autophagy for neurocardiac complications of diabetes mellitus.World journal of diabetes · 2015Article
- FoxO Transcription Factors and Regenerative Pathways in Diabetes Mellitus.Current neurovascular research · 2015Review
- Programming apoptosis and autophagy with novel approaches for diabetes mellitus.Current neurovascular research · 2015Review
- Bacille Calmette-Guérin/DNAhsp65 prime-boost is protective against diabetes in non-obese diabetic mice but not in the streptozotocin model of type 1 diabetes.Clinical and experimental immunology · 2013Article
- Novel directions for diabetes mellitus drug discovery.Expert opinion on drug discovery · 2013Review
- Inflammatory markers and haptoglobin polymorphism in Saudi with non-insulin-dependent diabetes mellitus.Global journal of health science · 2012Article
- Oxidant stress and signal transduction in the nervous system with the PI 3-K, Akt, and mTOR cascade.International journal of molecular sciences · 2012Review
- Mammalian target of rapamycin signaling in diabetic cardiovascular disease.Cardiovascular diabetology · 2012Review
- SIRT1: new avenues of discovery for disorders of oxidative stress.Expert opinion on therapeutic targets · 2012Review
- Erythropoietin: new directions for the nervous system.International journal of molecular sciences · 2012Review
- Targeting cardiovascular disease with novel SIRT1 pathways.Future cardiology · 2012Review
- Erythropoietin and Wnt1 govern pathways of mTOR, Apaf-1, and XIAP in inflammatory microglia.Current neurovascular research · 2011Article
- Erythropoietin employs cell longevity pathways of SIRT1 to foster endothelial vascular integrity during oxidant stress.Current neurovascular research · 2011Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
Abstract
Diabetes mellitus (DM) impacts a significant portion of the world's population and care for this disorder places an economic burden on the gross domestic product for any particular country. Furthermore, both Type 1 and Type 2 DM are becoming increasingly prevalent and there is increased incidence of impaired glucose tolerance in the young. The complications of DM are protean and can involve multiple systems throughout the body that are susceptible to the detrimental effects of oxidative stress and apoptotic cell injury. For these reasons, innovative strategies are necessary for the implementation of new treatments for DM that are generated through the further understanding of cellular pathways that govern the pathological consequences of DM. In particular, both the precursor for the coenzyme beta-nicotinamide adenine dinucleotide (NAD(+)), nicotinamide, and the growth factor erythropoietin offer novel platforms for drug discovery that involve cellular metabolic homeostasis and inflammatory cell control. Interestingly, these agents and their tightly associated pathways that consist of cell cycle regulation, protein kinase B, forkhead transcription factors, and Wnt signaling also function in a broader sense as biomarkers for disease onset and progression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.